Revenue
2025
Ping An Biomedical Co., Ltd. (PASW)
Price$0.1206Cached quote
Net income
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.8M | — | — | — | — |
| Gross profit | $133,376 | — | — | — | — |
| Gross margin | 2.78% | — | — | — | — |
| Operating expenses | $2.2M | — | — | — | — |
| Operating income | −$2.1M | — | — | — | — |
| Operating margin | −43.05% | — | — | — | — |
| EBITDA | −$2.1M | — | — | — | — |
| EBITDA margin | −43.04% | — | — | — | — |
| Net income | −$1.8M | — | — | — | — |
| Net profit margin | −37.57% | — | — | — | — |
| Basic EPSper basic share | -$0.10 | — | — | $0.35 | $0.38 |
| Diluted EPSper diluted share | -$0.10 | — | — | $0.35 | $0.38 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
XTX Topco Ltd | 134.56K |
CITADEL ADVISORS LLC | 114.18K |
Virtu Financial LLC | 37.02K |
TWO SIGMA SECURITIES, LLC | 13.08K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data